Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVEAL 2
2018-004114-17Phase 3
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Dec 2018
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human papillomavirus infection and cervical intraepithelial neoplasia (CIN) comparing VGX-3100 with Placebo (2 arms). Primary endpoint: Combined histopathologic regression and virologic clearance at Week 36.
02
Drugs
bizalimogene ralaplasmid
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on 2018-004114-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004114-17.